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Background: The protein products of the early genes E6 and E7 in high-risk HPV types 16 and 18 have been implicated
in the oncogenic capability of these viruses. Therefore, these peptides represent attractive vaccine therapy targets.
Methods: Thirty-two patients with advanced cervical cancer (HPV16 or 18 positive) were treated with HPV16 E6 (18–26)
(Arm A) or HPV16 E7 (12–20) peptide (Arm B) pulsed on PBMCs in order to illicit immune response against the relevant
peptide on both arms. These PBMCs were cultured for a short time (48 hours only) and in the presence of GM- CSF,
accordingly, they were identified as “Pre-Immature Dentritic Cells”.
Results: 51Cr release assay and ELISPOT demonstrated evidence of specific immune response against the relevant
peptide in 10/16 (63%) evaluable patients in arm A and 7/12 (58%) in arm B. HPV16 E6 was found to be homologous to
HPV18 E6 in both vivo and vitro. The median overall survival (OS) and progression free survival (PFS) for the full cohort
was 10.0 and 3.5 months, respectively. There were no RECIST responses in any patient. The majority of toxicities were
grade I and II.
Conclusions: We demonstrated the feasibility and ability of Pre-Immature Dentritic Cells pulsed with HPV16 E6 (18–26)
or HPV16 E7 (12–20) to induce a specific immune response against the relevant peptide despite the advanced disease of
the cervical cancer patients treated on this trial. We believe that this observation deserves further investigations.
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Cervical cancer is the third most common malignancy
in women and the fourth leading cause of female
cancer-related death worldwide [1]. More than 500,000
new cases of invasive cervical cancer are diagnosed
throughout the world yearly, accounting for over
275,000 deaths [1]. High-risk human papillomavirus (HPV)
has been implicated as an etiologic factor in almost all
cervical cancers [2]. Current therapeutic strategies for
advanced cervical cancer have proven ineffective [3,4].* Correspondence: skhleif@gru.edu
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unless otherwise stated.The recent development and FDA approval of two vac-
cines for HPV infection have represented a major
advance in cervical cancer prevention [5-8]. However,
the effect of prophylactic vaccines on women already
infected with HPV remains to be determined, and the
impact of prophylactic vaccines on the elimination of
cervical cancer is not expected to be apparent for de-
cades [9]. Accordingly, better therapeutic modalities for
advanced cervical cancer are needed.
HPV16 and HPV18 are the two most carcinogenic
HPV types amongst the high-risk HPV, and they are re-
sponsible for about 70% of invasive cervical cancer cases
[10,11]. HPV-E6 and E7 are the main oncogenic protein
products of high risk viruses and their continuous ex-
pression is necessary for the initiation and maintenanceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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antigens represent attractive targets for therapeutic can-
cer vaccines.
The methods of peptide vaccine administration have
varied. One way of delivery is by pulsing the peptide on
dendritic cells (DCs), which are the most potent profes-
sional antigen-presenting cells [15-17]. Dendritic cells
could be prepared as mature or immature cells. Imma-
ture DCs are Peripheral Blood Mononuclear Cells
(PBMCs) cultured for 5–7 days in GM-CSF and IL-4.
On the other hand, mature DCs are usually cultured
with the addition of pro-inflammatory cytokines for an
additional 24–48 hours [18,19]. Immature DCs can ef-
fectively capture antigens but, as opposed to mature
DCs, they lack the full T cell co-stimulatory activity [20].
Therefore, most trials that utilized DCs used the mature
type [17,21,22]. It is not clear whether maturation of DCs
is necessary to generate the needed immune response in
cancer vaccines. Furthernore, the preparation of DCs is
time consuming, expensive, and requires specialized fa-
cilities. Accordingly, here, we tested the feasibility of
using PBMCs in a state prior to being immature DCs;
“pre immature DCs”. PBMCs were cultured for a shorter
time (48 hours only) in the presence of GM- CSF only
and used to administer peptides E6 (18–26), or E7
(12–20), as cancer vaccines, to patients with advanced cer-
vical cancers. We found that this method of vaccination isTable 1 HPV16 E6 patient profile, clinical and immunological
Pt Age Path HPV type Disease extension # Vac Off-St
1A 39 ACA 18 Mets 8 PD
2A 46 SCC 16 Mets 1 SD/PP
3A 41 SCC 18 Mets 6 PD
4A 37 SCC 18 Mets 4 PD
5A 47 SCC 18 Mets 2 SD/PP
6A 36 ASCC 16 Mets 3 PD
7A 40 ASCC 18 Mets 4 PD
8A 48 ACA 18 Mets 4 PD
9A 40 SCC 18 Mets 1 SD/PP
10A 43 SCC 18 Mets 2 PD
11A 44 ACA 18 Mets 2 PD
12A 53 SCC 18 Mets 2 PD
13A 36 SCC 18 Mets 6 PD
14A 36 SCC 18 NED 6 PD
15A 38 SCC 18 NED 10 NED
16A 36 SCC 18 Mets 14 SD
17A 34 SCC 16 Mets 4 PD
18A 41 SCC 16 Mets 3 PD
Abbreviations: Pt Patient, Path Pathology, #Vac number of administered vaccines, IR
assay, ELISPOT Enzyme-Linked ImmunoSpot, SCC Squamous Cell Carcinoma, ACA Ad
PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, Mets mwell tolerated and capable of eliciting a specific immune
response against the relevant peptide.
Methods
Patient selection
Patients were assigned to two arms. Arm A received
HPV16 E6 (18–26) peptide, while patients on arm B
received HPV16 E7 (12–20) peptide pulsed on pre-
immature dendritic cells (PIDCs). Patients had histologi-
cally proven advanced cervical carcinoma, recurrent or
persistent disease despite prior treatment, and no evi-
dence of brain metastases. Patients on both arms had
HLA.A2.1 subtype. Patients who received the E6 peptide
harbored either HPV16 or 18 in their tumors, whereas
patients who received the E7 peptide harbored HPV16
(Tables 1 and 2). These selection criteria were based on
our pre-clinical studies which showed that HPV16 E6
(18–26) and HPV18 E6 (13–21) peptides are homolo-
gous. The sequence of both peptides is identical except
for amino acid number 21 where glutamine in HPV16
E6 (18–26) is replaced by aspartic acid in HPV 18 E6
(13–21). All enrolled patients met the protocol eligibility
criteria, including ECOG performance status of 0–1 and
life expectancy of more than 3 months. Main exclusion
criteria included history of autoimmune disease, and his-
tory of other malignancies except basal cell carcinoma of
the skin. Both the National Cancer Institute (NCI) andoutcome
udy response/reason PFS (ms) OS (ms) Cr-51 ELISPOT IR
8.0 20.1 - + +
S 0.7+ 1.4 ND ND ND
5.9 18.6 - - -
3.6 9.7 - + +
S 2.8+ 4.9 - - -
1.6 8.7 + NA +
4.6 6.0 - - -
3.4 10.0 - NA -
S 4.4+ 5.2 ND ND ND
1.4 4.3 - + +
1.5 4.9 + - +
1.6 11.1 - + +
5.6 10.7 - + +
5.3 20.5 NA - -
67.1+ 67.1+ - + +
115.9+ 115.9+ NA + +
0.4 3.9 NA + +
1.5 3.7 NA - -
Immune Response, ND Not done, NA Not available, Cr-51 Chromium-51 release
enocarcinoma, ASCC Adenosquamous Carcinoma, NED No Evidence of Disease.
etastatic disease, PFS Progression Free Survival, OS Overall Survival, ms Months.
Table 2 HPV16 E7 Patient profile, clinical and immmunological outcome
Pt Age Path HPV type Disease extension #Vac Off-Study response/reason PFS (ms) OS (ms) Cr-51 ELISPOT IR
1B 37 ACA 16 Mets 9 PD 10.0 25.2 + N/A +
2B 40 SSC 16 Mets 5 PD 6.3 19.9 + N/A +
3B 41 SSC 16 Pelvis 4 PD 4.6 8.5 + + +
4B 33 SSC 16 Pelvis 2 PD 2.4 13.9 - NA -
5B 53 SSC 16 Mets 4 PD 1.6 7.2 - + +
6B 37 SSC 16 Pelvis 1 PD 1.5 4.4 ND ND ND
7B 48 SSC 16 Mets 4 PD 1.7 6.3 - - -
8B 53 SSC 16 Mets 4 PD 3.6 42.6 - - -
9B 37 SSC 16 Pelvis 6 PD 5.3 7.4 - + +
10B 68 SSC 16 Pelvis 3 PD 2.5 5.5 - - -
11B 49 SSC 16 Mets 8 PD 7.7 7.7+ + + +
12B 51 SSC 16 Mets 2 PD 1.6 18.4 - - -
13B 45 SSC 16 Mets 6 SD/W 7.5+ 7.5+ - + +
14B 28 SSC 16 Mets 4 PD 3.5 11.5 NA NA NA
Abbreviations: Pt Patient, Path Pathology, #Vac number of administered vaccines, IR Immune Response, ND Not done, NA Not available, Cr-51 Chromium-51 release
assay, ELISPOT Enzyme-Linked ImmunoSpot, SCC Squamous Cell Carcinoma, ACA Adenocarcinoma, ASCC Adenosquamous Carcinoma, NED No Evidence of Disease.
PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, Mets metastatic disease, PFS Progression Free Survival, OS Overall Survival, ms Months.
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Review Boards (IRBs) approved the protocol and the pa-
tients’ consent was obtained prior to enrollment.
Peptide selection
Using computer-based prediction web sites such as the
syfpeithi [(http://www.syfpeithi.de/Scripts/MHCServer.dll/
EpitopePrediction.htm)] and the Bimas [(http://thr.cit.nih.
gov/molbio/hla_bind/)], the HLA-A2 restricted epitopes in
the E6 and E7 sequence were detected. E6 (18–26) peptide
(PR-KLPQLCTEL-LYS-9-LEU) and E7 (12–20) peptide
(MLDLQPETT-MET-9-THR) were the strongest A2
binders. Therefore, they were used in this trial.
Vaccine preparation
Pre-immature Dendritic cells (PIDCs) were prepared
from peripheral blood mononuclear cells (MNCs) ob-
tained by either automated leukapheresis (Aph) or whole
blood (WB) collection. The sequence of MNC collection
for vaccine preparation in each patient was Aph, Aph,
WB, WB, with repetition of this sequence for subsequent
cycles. For Aph cycles, patients underwent leukapheresis
on the Fenwal CS3000 blood cell separator using antic-
oagulation with ACA-A and peripheral or central venous
access, with a volume processed of 3–5 liters. MNCs
were purified from the leukapheresis collection by an au-
tomated ficoll-hypaque density gradient procedure, and
2 × 109 cells were placed into culture for 2 days with
RPMI 1640 (Cambrex, Walkersville, MD) supplemented
with GM-CSF, 0.4 ng/ml, and 5% autologous heat-
inactivated plasma in 162 cm2 flasks (Costar, Myriad,San Diego, CA), at 37°C, with 5% CO2. After 40–46 hours,
cells were concentrated to 2 × 107/ml, and 1 × 109 cells
were pulsed with the HPV16 E6(18–26) peptide (PR-
KLPQLCTEL-LYS-9-LEU) or HPV16 E7 (12–20) peptide
(MLDLQPETT-MET-9-THR), 10 μmolar, for 2 hours,
washed, and resuspended in PlasmaLyte A with 2% au-
tologous plasma or serum to a volume of 25–40 ml, and
irradiated with 25 Gy from a Cesium source. For WB cy-
cles, 100–150 ml of peripheral venous blood was drawn
into heparin sulfate (10 units/ml blood). MNCs were sepa-
rated on a ficoll hypaque gradient, washed and resus-
pended. 70 × 106 cells were cultured at a concentration of
4–5 × 106/ml in RPMI 1640 (Cambrex) with 5% heat-
inactivated autologous serum or allogeneic AB human
serum, supplemented with 0.4 ng/ml of GM-CSF at 37°C
with 5% CO2. The HPV16 E6 peptide, 10 μmolar, was
added at initiation of culture, and was therefore present
for the entire 2 day culture duration. After 40–46 hours,
the peptide-pulsed cells were harvested, washed, and re-
suspended in PlasmaLyte A with 2% autologous serum or
allogeneic AB serum to a volume of 6 ml, and irradiated
with 25 Gy. For Aph cycles, infusion of up to 1 × 109
peptide-pulsed PIDCs was allowed, with a cell concentra-
tion of 20 × 106/ ml, whereas the WB cycles allowed a
maximum of 70 × 106 cells, with a cell concentration
of 10 × 106/ml.
Vaccine administration
Prior to vaccine administration, peptide hypersensitivity
testing was done. Briefly, 1 μg of peptide dissolved in
0.1 ml of preservative-free normal saline was injected
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observed for 1 hour. The peptide-pulsed PIDCs were in-
fused intravenously (IV) at a rate of 5 ml over 1–2 min
through a sterile 110 micron filter needle. Vaccination
was repeated at week 3, then every 4 weeks for a total of
14 vaccinations or until disease progression. Patients
were observed for another hour after vaccination.
Clinical monitoring
Patients were evaluated for toxicity and tumor re-
sponse during treatment and up to two years after the
last vaccination. Tumor response was assessed by phys-
ical exam and by the appropriate imaging technique
(CT-scan) according to RECIST criteria at baseline,
then every 2 vaccinations during therapy and every
3 months during follow-up. Patients were taken off
protocol because of either deterioration in the perform-
ance status, disease progression or withdrawal from the
study. Disease progression was defined per the modi-
fied WHO criteria of progression as the appearance of
new lesions and/or a 25% increase of measurable lesions
as evident by CT-scan. Once patients had progressed,
follow-up was not required except to document late
toxicities and death. Adverse events and toxicities were de-
fined and graded according to the NCI Common Toxicity
Criteria.
Immunological testing
To assess the immune response, lymphocytes were iso-
lated from PBMC. Immunologic testing was performed
using Chromium-51 release assay (51Cr release assay)
against cervical cancer cell lines as described below
and Enzyme-Linked ImmunoSpot (ELISPOT). The post-
vaccination samples were tested at the date of the
next administered vaccines prior to each vaccination
and compared to pre-vaccination samples. The pre-
vaccination and post-vaccination samples were frozen
and assayed at the same time. The immune response
was considered positive for patients who demonstrated a
positive immune response by either ELISPOT, 51Cr release
assay or both.
Cell lines
Cervical cancer cell lines used in this trial were either
from the ATCC (Mannassas, VA) including the ME180,
Caski and MS751 or established at the NCI (Bethesda,
MD) like the Cav cervical cancer cell line. All cells were
tested in our lab for HLA and HPV typing. Caski,
MS751 and Cav are all HLA-A2 positive cell line
while ME180 is an A2 negative cell line. Caski har-
bors the HPV16 genome while MS751 and the Cav har-
bor the HPV18 genome (low and high number of copies
respectively). All cells grew in RPMI supplemented with
10% FCS, Penicillin, L-Glutamine and Sodium Pyruvate.Chromium-51 release assay (51Cr release assay)
The cervical cancer cell lines mentioned above were
used as targets in the cytotoxic T lymphocyte (CTL)
assay. The cytolytic activity was measured by using the
4-hour 51Cr release assay. Lymphocytes were prepared
from PBMC. These cells were selected and expanded
in vitro in the presence of 1–20 μM of E6 peptide with
5 IU/ml of IL-2 (Chiron, Emeryville, CA) added on day
3 for 7 days. This 7 day cycle was repeated one more
time, after which the cells were harvested and tested for
specific cytolytic activity against E6 or E7 peptide pulsed
autologous APC’s (EBV transformed B cells) or tumor
cell lines harboring the HPV genome. Target cells were
washed with RPMI medium and labeled with 200 μCi
51Cr sodium dichromate in the presence or absence of
10 μM of E6 or E7 peptide for 2 hours, after which tar-
get cells were washed and plated in 96 well round
bottomed plates. Effectors were added to labeled targets
at the desired effector to target ratio. The plates were
centrifuged at 500 rpm for 5 min., and incubated at
37°C for 4 hours. Supernatants were harvested using
a Skatron supernatant harvesting device, and the samples
counted on a gamma counter. The percent specific lysis
was determined, on triplicate samples, by the following
formula:
Percent specific lysis ¼ experimental release
‐ spontaneous release  100
Maximum release - spontaneous release
A result was considered positive with a two fold increase
or more in lytic units pre-immunization. If there was
no detectable pre-immunization specific lysis, a post
immunization lysis of greater than 10% above the non-
peptide was considered positive, with an Effector:Target
(E:T) ratio specified at 50:1. If an E:T ratio of 50:1 was
not tested, the next highest ratio was used. In some pa-
tients we established CTL and tumor cell lines for future
use in studies of antigen specificity.
Enzyme-linked ImmunoSpot (ELISPOT) assay
ELISPOT assays were performed at the Laboratory of Cell-
Mediated Immunity, SAIC-Frederick (CLIA-certified lab).
Two frozen normal donor controls with known respon-
sive values were run with each assay to assure quality
control of the assay results. For all assays, at least one
of the two controls was within 2 standard deviations of
the laboratory-generated means for CMV and CEF. All
assays were performed on 7–8 day in vitro stimulated
PBMCs (100 K/well) as the effectors and peptide-pulsed
autologous PBMCs (100 K/well) as the antigen present-
ing cells (APCs). When possible, PBMCs from the earli-
est time point were used as the APCs. However, if this
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to make sure they were not producing any spots. Briefly,
the day before assay setup, 96-well polyvinylidene fluor-
ide (PVDF) membrane, HTS opaque plates (Millipore,
Billerica, Massachusetts, MSIPS4W10) were coated over-
night with a 1:100 dilution of anti-human IFN-γ capture
antibody (1 mg/mL, Mabtech Inc., Mariemont, OH,
Cat# 3420-3-1000) in Dulbecco’s phosphate buffered
saline (DPBS) at room temperature. Antibody-coated
plates were washed four times in DPBS the next day
and blocked with 5% human AB ELISPOT medium at
37°C for approximately 2 hours. 1 × 105in vitro stimu-
lated PBMCs and 1 × 105 autologous, peptide-pulsed
PBMCs were plated per well. The plates were incubated
for 18–20 hours at 37°C. The next day, the plates were
manually washed six times with 0.05% Tween 20 in
DPBS, followed by a 2-hour incubation at room tem-
perature with a 1:2000 dilution of the biotinylated sec-
ondary antibody, anti-human IFN-γ (1 mg/mL Mabtech
Inc., Mariemont, OH, Cat# 3420-6-1000) in DPBS/1%
bovine serum albumin/0.05% Tween. After incubation
and four washes in DPBS to remove excess antibody,
a 1:3000 dilution of streptavidin alkaline phosphatase
(Mabtech, Mariemont, OH, Cat# 3310–10) in DPBS/1%
bovine serum albumin, was added to each well for 1 hour
at room temperature followed by 4 manual washes in
DPBS. Finally, the BCIP/NPT substrate, 100 μl/well,
(KPL, Gaithersburg, Maryland, Cat# 50-81-08) was added
for 7–10 minutes, resulting in the development of spots.
The reaction was stopped by washing three times in dis-
tilled water. Plates were dried overnight and the spots
were visualized and counted using the ImmunoSpot
Imaging Analyzer system (Cellular Technology Ltd.,
Cleveland, OH). ELISPOT results were expressed as the
“number of spots per 106 responder cells” after subtracting
background spots obtained in wells of effectors with non-
pulsed PBMCs. For each subject, PBMCs obtained before
and after vaccination were analyzed in the same assay to
avoid inter-assay variability. A post-immunization fold in-
crease >2 compared to pre-immunization was considered
a positive response.
Statistical analysis
This study was carried out as a pilot trial to gain experi-
ence administering vaccines with the E6 and E7 peptide.
The primary objectives of this study was to determine
whether vaccinating advanced cervical cancer patients
with Pre-Immature Dendritic Cells (PIDC) pulsed with
HPV16 E6 or E7 peptide is safe and capable of eliciting
specific immune response against the relevant adminis-
tered peptide. It was intentionally small in order to have
adequate numbers for evaluation of feasibility and im-
mune response, but limited information on clinical effi-
cacy. All results presented are intended to be hypothesisgenerating in view of the intention of the trial and the
limited number of subjects treated.
As secondary outcomes from the trial, overall survival
survival (OS) and progression free survival (PFS) were
computed from the date the consent was signed until
the date the patient died, progressed or was last followed
as appropriate. The Kaplan-Meier method was used to
estimate the probability of survival or progression free
survival as a function of time.
Results
Patient profile
Thirty-two patients with advanced cervical cancer were
enrolled on this trial. Eighteen patients received the
HPV1A6 E6 (18–26) peptide (arm A) and 14 patients
received the HPV16 E7 (12–20) peptide (arm B). The
patients’ characteristics are summarized in Table 1
(Arm A) and Table 2 (Arm B). Age ranged from 28 to
68 years with a mean of 40.8 in arm A and 44.2 in arm B.
Twenty six patients had squamous cell carcinoma (13 in
each arm), 4 patients had adenocarcinoma (3 in arm A and
1 in arm B), and 2 patients in arm A had adeno-squamous
carcinoma. In arm A, four patients’ tumors harbored
HPV16 and fourteen patients’ tumors harbored HPV18.
Whereas in arm B, all patients’ tumors harbored the
HPV16 subtype. Patients in both arms were heavily pre-
treated; Twenty two patients underwent at least one sur-
gery with a course of radiation. Two patients received at
least one surgery with a course of chemotherapy. The
remaining eight patients received only radiation and
chemotherapy. Patients had measurable disease on enroll-
ment except patients 14A and 15A who had no evidence
of disease. Patient 14A had stage IB on diagnosis which
was treated with surgery followed by adjuvant radiation
therapy. Subsequently, further treatment with radiation
therapy and chemotherapy was given for recurrent disease
in the para-aortic lymph nodes. Patient 15A was diagnosed
with stage IIB during laparotomy, and treated with adju-
vant radiation therapy. However, this patient developed
pulmonary metastasis and was treated with radiation and
chemotherapy followed by thoracotomy.
Immunological data
Phenotype of the pre-immature dendritic cells (PIDCs)
FACS analysis was done on the PIDCs before vaccine
administration to document their phenotype. The data
was further confirmed using PBMCs from healthy do-
nors. Prior to the GM-CSF incubation; the PIDCs were
all monocytes expressing CD14 and they did not ex-
press any of the antigen presenting cell surface markers.
After two days in culture in the presence of GM-CSF,
and pulsing for two hours with the HPV16 E6 or E7
peptide, in spite of the persistent expression of CD14
at slightly lower levels (Figure 1A), CD14 positive
Figure 1 FACS analysis showing the phenotype of PIDCs used in the vaccine preparation. A) After a two day incubation in the presence
of GM-CSF, and pulsating with HPV E7 peptide for two hours, CD14 positive cells persistently expressed CD14 at a slightly lower level. B) CD14
positive cells expressed a higher level of CD80 following incubation with GM-CSF and HPV E7 peptide. C) CD14 positive cells expressed a higher
level of CD86 following incubation with GM-CSF and HPV E7 peptide. D) CD14 positive cells expressed a higher level of CD1a following incubation
with GM-CSF and HPV E7 peptide. E) CD14 positive cells expressed a higher level of the Mannose receptor (CD206) following incubation with
GM-CSF and HPV E7 peptide. F) HLA-DR was up-regulated in CD14 positive cells following incubation with GM-CSF and HPV E7 peptide.
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express antigen presenting cell associated surface markers
(CD80, CD86, CD1a and Mannose receptor (CD206))
(Figure 1B-E). Furthermore, there was up regulation in
HLA-DR (Figure 1F).
The cross reactivity between HPV16 E6 and HPV18 E6
To test whether E6 protein is processed and presented
in the proper context of MHC class I and to test the
ability of T-cells generated by HPV16 E6 to cross react
with an internally processed HPV18 E6, we tested the
ability of post vaccination PBMCs to lyse established
HLA-A2 positive cervical cancer cell lines harboringeither the HPV16 or HPV18 genome. We found that these
primed T-cells were able to lyse Caski cells (HLA-A2
and HPV16 positive), Cav cell line (HLA-A2 with a
high number of copies of HPV18) and, to a lesser ex-
tent, the MS751 cell line (HLA-A2 harboring lower
number of copies of HPV18) but not the HLA-A2 and
HPV negative cervical cancer cells (ME180). We were
able to see specific lysis in those cell lines and the lysis
was higher in cell lines that carry higher number of
copies of HPV (Figure 2). Similarly, the effector cells
generated through the E7 vaccine were tested against
tumor cells either expressing the HPV16 E7 genome or
HPV16 E7 negative cell line. We were able to detect
Figure 2 The cytolytic activity of patient 6A’ PBMCs post one vaccination. Cervical cancer cell lines were used as target cells. Caski (HPV16
positive, HLA-A2 cell line) closed squares; CAV (HPV 18 high and HLA-A2 cell line), open circles; MS751 (an HPV 18 low, HLA-A2 cell line), open
diamonds; ME180 (HPV negative, HLA-A2 negative cervical cancer cell line), open triangles. Highest percentage of specific lysis was seen with the
Caski and Cav cell lines, followed by the MS751 and only background level lysis was seen when the ME180 cell line was used as a target.
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tive ones. Furthermore, effector cells were able to lyse
only the HLA-A2 positive cell lines and not the HLA-
A2 negative ones (data not shown).
Immune response
Immunological responses were evaluated in 28 out of 32
treated patients (Tables 1 and 2). Three patients were
excluded from the analysis since they received only one
vaccine due to disease progression (2A, 9A, 6B), and one
patient (14B) was not tested for an immune response
due to lack of sufficient cell numbers to reproduce the
results. Seventeen out of the 28 (61%) evaluated patients
had positive immune responses by either ELISPOT,
51Cr release assay, or both [10/16 (63%) in arm A, and
7/12 (58%) in arm B]. The immune response data for
both ELISPOT and 51Cr release assay are presented
in Additional file 1: Figures S1 and Additional file 2:
Figure S2.
Clinical response
Clinical response was evaluated in 29 out of the 32
treated patients (Tables 1 and 2). Three patients (2A, 9A
and 6B) were excluded from the analysis since they re-
ceived only one vaccine due to poor performance status.
Out of the 29 evaluable patients the clinical outcome
was as follows: Twenty five patients had progression of
disease during the course of treatment (13/16 on arm A
and 12/13 patients on arm B); one patient (5A) was
taken off the study due to poor performance status after
receiving 2 vaccine doses; one patient (#13B) decided to
withdraw from the study and had a stable disease after
receiving 6 vaccine doses; and the remaining 2 patients(#15A and 16A) completed the treatment without dis-
ease progression. Patient 15A was enrolled on the study
with NED after being treated with 2 surgeries, 2 courses
of radiation therapy and one chemotherapy regimen.
This patient received a total of 10 vaccine doses and
continued to have no evidence of disease as of the last
follow up (67.1 months). Patient 16A was enrolled on
the study with stage IV disease after being treated with
radiation therapy and 2 courses of chemotherapy. This
patient completed a total of 14 vaccine doses and con-
tinued to have a stable disease, as of the last available
follow up (115.9 months). There were no RECIST re-
sponses in any patient. The median overall survival (OS)
and progression free survival (PFS) for the full cohort
was 10.0 and 3.5 months, respectively (Figure 3). Arm A
had a median OS and PFS of 9.7 and 3.6 months, re-
spectively, while patients on arm B had a median OS
and PFS of 11.4 and 3.5 months, respectively. Eighteen
patients received fewer than five vaccine doses and had
a median OS and PFS of 7.2 and 1.7 months, respect-
ively. On the other hand, 11 patients who were able
to receive five or more vaccine doses had a median OS
and PFS of 20.1 and 6.9 months, respectively. Patients
who had an immune response had a median OS and
PFS of 8.7and 5.3 months, respectively, while the non-
immune responders had a median OS and PFS of 6.3
and 2.8 months, respectively.
Safety and toxicity
The vaccine was well tolerated. No allergic reaction to
the vaccine was reported in either arm. The majority of
toxicities were grade I or II, with fatigue being the most
common occurring in 12/18 (67%) patients in arm A
Figure 3 Progression free survival and overall survival for the full cohort. Progression free survival (A) and overall survival (B) for the full
cohort. PFS was calculated as time from the date of consent until evidence of disease progression or last follow-up. OS was calculated as time
from consent date until death or last follow-up.
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were reported in both arms, majority of which were at-
tributed to the disease process. These events included:
anemia, nausea, vomiting, shortness of breath, chest pain,
pyelonephritis, and thrombocytopenia. No grade IV tox-
icity was reported on either arm (Table 3).
Discussion
In this pilot study Pre-Immature Dentritic Cells (PIDC)
pulsed with HPV16 E6 (18–26) or HPV16 E7 (12–20)
peptides were found to be capable of generating specific
immune response as evident by the 51Cr release CTL or
ELISPOT assay. The majority of patients on both arms
had a measurable increase in the number of IFN-γ se-
creting cells post vaccination. In the cytolytic assay, we
were able to show that PBMCs of patients who receivedthe vaccine were able to recognize and lyse target cells
pulsed with the E6 or E7 peptide. In addition, we showed
that the HPV16 E6 is homologous to HPV18 E6 and cross-
react. We were able to demonstrate that the immune re-
sponse induced by HPV16 E6 can specifically lyse cervical
cancer cell lines harboring either HPV16 (caski cell line) or
HPV18 (Cav and MS751) in vitro. These findings were also
evident in ex vivo since patients in the E6 arm developed
an immune response against HPV16 E6 peptide whether
they expressed HPV16 or 18 on their tumors. Accordingly,
since those two peptides are able to cross react either of
them can be used for vaccination of both groups of pa-
tients with HPV16 and HPV 18 expressing tumors.
The antigen presenting cells used in this trial were
autologous PBMCs cultured only for 48 hours in the
presence of GM-CSF, and hence we called them
Table 3 Toxicities





Chest pain 1 (18A)
Pyelonephritis 1 (9A)
Thrombocytopenia 1 (14B)
Abbreviations: SOB shortness of breath.
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61% of patients developed immune response against the
relevant peptide indicating that the PIDCs were able to
function normally and proved to be potent APCs, even
though they don’t express all surface markers of DCs.
These PIDCs possess a great advantage over regular DCs
as they can be generated in a shorter time, can give a
higher cell yield, and are not dependent on the cytokines
in the culture such as IL-4.
Two previously conducted clinical trials demonstrated
the immunogenicity of the recombinant E7 protein pulsed
on mature DCs in advanced cervical cancer patients
[21,22]. Ferrara et al. treated patients with recombinant
HPV16 E7 or HPV18 E7 protein pulsed on mature DCs
and administered subcutaneously and demonstrated the
generation of immune response in 3 of the 11 treated pa-
tients (27%) [21]. Santin et al. treated patients with recom-
binant HPV16 E7 or HPV18 E7 protein pulsed on mature
DCs and administered subcutaneously in combination with
low dose IL-2 and showed positive immune responses in
all tested patients (4/4, 100%) [22]. A live recombinant vac-
cinia virus expressing the E6 and E7 proteins of HPV16
and 18 was also investigated as a therapeutic vaccine in the
advanced cervical cancer setting [23]. Only 1/3 (33%) of
evaluated patients had a positive CTL response following
re-stimulation with E6 and E7 peptides. More recently,
Melief et al. investigated a mix of long peptides from the
HPV-16 E6 and E7 in incomplete Freund’s adjuvant in 20
patients with HPV16 positive, high-grade vulvar intrae-
pithelial neoplasia. Fifteen of 19 patients (79%) had clinical
responses and all patients had vaccine-induced T-cell re-
sponses [24]. Indeed, it would be difficult to compare our
findings to others given the different methods of vaccin-
ation and the variety of immune assays used to detect the
immune response.
Although this trial was not powered to test for clinical
efficacy, it revealed some interesting clinical findings.
For the full cohort, the median overall survival (OS) and
progression free survival (PFS) was 10.0 and 3.5 months,
respectively which is encouraging given the poor expected
survival in this population of patients when treated withstandard chemotherapy (median OS of 4.9 months) [3].
Moreover, it is noticeable that patients who received five
or more vaccine doses had a longer median OS and PFS
of 20.1 and 6.9 months, respectively. Because this is not a
randomized study, it would be difficult to determine
whether the longer survival in this group of patients is due
the higher number of vaccine doses they received or to
their tumors’ biology which allowed them to survive lon-
ger and therefore to receive more vaccines. Furthermore,
the disconnection between the immune and the clinical
response could be related to the expansion of inhibitory
immune cells such as T-regulatory cells (T-regs) and
myeloid-derived suppressor cells (MDSCs) or the activa-
tion of other immunosuppressive pathways such as the
PD-L1/PD-1 pathway. However, because of the small co-
horts tested on this trial we cannot conclude a relationship
between OS or PFS and immune response.
In summary, this pilot study represents a proof of con-
cept for using pre-immature dendritic cells (PIDCs) for
peptide delivery in cancer vaccine development. This
method should be further investigated in future clinical
trials. In addition, future directions should focus on in-
vestigating this method of peptide vaccination in a popu-
lation of patients with early stage of disease in order to
allow time for the generated immune response to be
translated to a clinical effect. Combining this method of
vaccination with other modalities such as chemotherapy,
radiation therapy or immune modulators should be also
considered in the future.
Conclusion
In summary, our trial confirmed the feasibility and safety
of using HPV16 E6 and E7 peptide vaccine as a person-
alized treatment for patients with advanced cervical can-
cer. These peptide vaccines were capable of generating a
specific immune response against the relevant peptide.
Further studies are needed to test these peptide vaccines
in early disease setting and in combination with other
modalities such as immune modulators.Additional files
Additional file 1: Figure S1. Immune responses in patients on arm A
(HPV16 E6). Immune responses of patients on arm A to HPV16E6 peptide
in red compared with no peptide in blue. Immune responses were
measured by ELISPOT (Panel A) or 51Cr release assay (Panel B). Abbreviations:
Pre-vaccine, Pre-vaccination sample; Post-V, Post-vaccination sample marked
by the vaccine number; f/u, Follow up sample marked in months (ms) from
the last post vaccine sample.
Additional file 2: Figure S2. Immune responses in patients on arm B
(HPV16 E7). Immune responses of patients on arm B to HPV16E7 peptide
in red compared with no peptide in blue. Immune responses were
measured by ELISPOT (Panel A) or 51Cr release assay (Panel B). Abbreviations:
Pre-vaccine, Pre-vaccination sample; Post-V, Post-vaccination sample marked
by the vaccine number; f/u, Follow up sample marked in months (ms) from
the last post vaccine sample.
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PIDC: Pre-immature dendritic cells; HPV: Human papilloma virus;
PBMCs: Peripheral blood mononuclear cell; GM- CSF: Granulocyte
macrophage colony-stimulating factor; 51Cr release: Chromium-51 release
assay; ELISPOT: Enzyme-linked ImmunoSpot; OS: Overall survival;
PFS: Progression free survival; RECIST: Response evaluation criteria;
DCs: Dendritic cells; IL: Interleukin; ECOG: Eastern cooperative oncology
group; NCI: National cancer institute; NNMC: National naval medical center;
IRBs: Institutional review boards; MNCs: Peripheral blood mononuclear cells;
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CTL: Cytotoxic T Lymphocyte; TLN: Tumor-draining lymph nodes;
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